Clinical Trial Update: Tislelizumab With Anlotinib and Chemotherapy for Second-line Treatment of Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating tislelizumab with anlotinib and chemotherapy as second-line treatment for pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Neoplasms

Drugs mentioned

• Anlotinib (anlotinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: First Affiliated Hospital Xi'an Jiaotong University | Conditions: Pancreatic Neoplasms | Phase 2 | Status: UNKNOWN